Literature DB >> 8195034

The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.

L D Skarsgard1, A Vinczan, M W Skwarchuk, D J Chaplin.   

Abstract

PURPOSE: We examined the effect of acidic pH and hypoxia on the cytotoxicity of SR4233 and mitomycin C in vitro. METHODS AND MATERIALS: The importance of tumor microenvironment to the response of solid tumors to cytotoxic treatment is well established. The bioreductive drug SR4233 has a very substantial selective toxicity for hypoxic cells. We have used both Chinese hamster and human tumor cells to investigate the influence of low pH and hypoxia on the response of cultured cells to treatment with SR4233 or mitomycin C.
RESULTS: We found that low pH (6.6) had little effect on the hypoxic toxicity of SR4233; under aerobic conditions, however, low pH substantially increased the cytotoxic effects of 1 h exposure to SR4233, with drug dose enhancement ratios (ER) of 3.9 and 2.5 in V79 and HT-29 cells, respectively. In similar studies with mitomycin C, hypoxia had little effect on the cytotoxicity of mitomycin C in V79 cells, though a low pH of 6.6 enhanced the cytotoxicity under both aerobic and hypoxic conditions (ER approximately 2). In HT-29 cells, neither low pH nor hypoxia had any significant effect on mitomycin C toxicity.
CONCLUSION: Low pH, like hypoxia, is a common feature of solid tumors and can be an important determinant of the cytotoxic effect of bioreductive drugs such as SR4233 and mitomycin C.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195034     DOI: 10.1016/0360-3016(94)90290-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.

Authors:  W C Yen; T Schmittgen; J L Au
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

2.  Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.

Authors:  Bo Hong; Vivian W Y Lui; Edwin P Hui; Margaret H L Ng; Suk-Hang Cheng; Fion L Sung; Chi-Man Tsang; Sai-Wah Tsao; Anthony Tak-Cheung Chan
Journal:  Invest New Drugs       Date:  2009-12-16       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.